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a b s t r a c t
Endothelin-1 (EDN1) inﬂuences both craniofacial and cardiovascular development and a number of adult
physiological conditions by binding to one or both of the known endothelin receptors, thus initiating
multiple signaling cascades. Animal models containing both conventional and conditional loss of the
Edn1 gene have been used to dissect EDN1 function in both embryos and adults. However, while
transgenic Edn1 over-expression or targeted genomic insertion of Edn1 has been performed to under-
stand how elevated levels of Edn1 result in or exacerbate disease states, an animal model in which Edn1
over-expression can be achieved in a spatiotemporal-speciﬁc manner has not been reported. Here we
describe the creation of Edn1 conditional over-expression transgenic mouse lines in which the chicken β-
actin promoter and an Edn1 cDNA are separated by a strong stop sequence ﬂanked by loxP sites. In the
presence of Cre, the stop cassette is removed, leading to Edn1 expression. Using the Wnt1-Cre strain, in
which Cre expression is targeted to the Wnt1-expressing domain of the central nervous system (CNS)
from which neural crest cells (NCCs) arise, we show that stable chicken b-actin-Edn1 (CBA-Edn1)
transgenic lines with varying EDN1 protein levels develop defects in NCC-derived tissues of the face,
though the severity differs between lines. We also show that Edn1 expression can be achieved in other
embryonic tissues utilizing other Cre strains, with this expression also resulting in developmental
defects. CBA-Edn1 transgenic mice will be useful in investigating diverse aspects of EDN1-mediated-
development and disease, including understanding how NCCs achieve and maintain a positional and
functional identity and how aberrant EDN1 levels can lead to multiple physiological changes and
diseases.
& 2015 Elsevier Inc. All rights reserved.
Introduction
Endothelin-1 (EDN1) is a 21 amino acid (aa) peptide that has a
variety of functions in both embryos and adults. Of the three endo-
thelin ligands (EDN1, 2 and 3), EDN1 can bind to either of the two
known endothelin receptors, Endothelin-A (EDNRA) and Endothelin-B
(EDNRB) (Takayanagi et al., 1991; Yanagisawa, 1994). EDN1 was isol-
ated and characterized based on its potent vasoconstrictive activity
(Yanagisawa et al., 1988), where its action on smooth muscle cells
results in changes in vascular tone, primarily acting through EDNRA.
Numerous roles for EDN1 in vascular diseases of the liver, lungs and
kidneys have been described, including chronic obstructive pulmonary
disease (COPD) (Dorrington, 1999; Polikepahad et al., 2006), chronic
kidney disease (Dhaun et al., 2012; Gagliardini et al., 2011), hyperten-
sion (Moorhouse et al., 2013; Speed and Pollock, 2013) and cirrhosis
(Moore, 2004). Elevated EDN1 levels have also been implicated in
diseases that include Alzheimer's disease (Palmer et al., 2013), Sickle
cell anemia (Morris, 2008), inﬂammatory bowel disease (Angerio et al.,
2005), demylinating diseases (Hammond et al., 2014; Haufschild et al.,
2001) and infectious diseases (Freeman et al., 2014). In addition, EDN1
is also implicated in multiple aspects of cancer progression, including
epithelial to mesenchymal transition (EMT) (Bagnato and Rosano,
2007) and in stimulating tumor angiogenesis (Knowles et al., 2005).
While early studies predicted that targeted disruption of Edn1 or
Ednra in mice would lead to resistance to hypertension, Edn1 /
(Kurihara et al., 1994) and Ednra / (Clouthier et al., 1998) embryos
were born with numerous craniofacial and cardiovascular defects due
to disruption in cranial and cardiac neural crest cell (NCC) patterning
during early embryogenesis. Edn1 is ﬁrst expressed in the ectoderm,
mesoderm and endoderm of the mandibular portion of the ﬁrst
pharyngeal arch and arches 2–6, transient structures on the ventral
embryo surface that give rise to most facial and neck structures
(Maemura et al., 1996) (Clouthier et al., 1998; Yanagisawa et al., 1998a;
Yanagisawa et al., 1998b). In contrast, Ednra expression is found in
all cranial NCCs immediately following emigration of NCCs from
the neural tube (Clouthier et al., 1998; Yanagisawa et al., 1998a;
Yanagisawa et al., 1998b). From targeted inactivation studies in mice
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and analysis of mutant and morphant zebraﬁsh, EDN1-mediated
EDNRA signaling is now known to establish the identity of NCCs in
the mandibular portion of the ﬁrst pharyngeal arch (Kimmel et al.,
2003; Miller and Kimmel, 2001; Miller et al., 2000a; Miller et al.,
2007; Nair et al., 2007; Ozeki et al., 2004; Ruest et al., 2004; Walker et
al., 2007; Walker et al., 2006). In mice, loss of this signaling results in
a homeotic transformation of lower jaw structures into more max-
illary like structures, including duplication of the maxilla and much of
the secondary palate in the lower jaw (Ruest et al., 2004). Similar
changes in the maxilla are observed in human Auriculocondylar
Syndrome (ACS) patients, in which downstream mediators of EDN1/
EDNRA signaling are disrupted (Clouthier et al., 2013; Rieder et al.,
2012), illustrating the conserved nature of this pathway in vertebrate
facial development. In contrast to these ﬁndings, the maxilla of
embryos in which an Edn1 cDNA has been inserted into the Ednra
locus undergoes transformation into a mandible-like structure (Sato
et al., 2008b). This change illustrates that while all cranial NCCs are
competent to respond to EDNRA signaling, the conﬁnement of
signaling is achieved by restricting Edn1 expression to the mandibular
arch. However, the ability to induce Edn1 expression in a speciﬁc
spatio-temporal manner does not exist.
Because of neonatal lethality associated with targeted deletion of
either Edn1 or Ednra, experiments designed to better understand the
role of Endothelin signaling in adult hypertension and cardiac function
have used a conditional loss of function approach (Kedzierski et al.,
2003; Shohet et al., 2004). In addition, transgenic mouse strains in
which Edn1 expression was driven by its own promoter (Hocher et al.,
1997; Shindo et al., 2002) or an endothelial-speciﬁc promoter (Amiri
et al., 2004) have further illustrated roles for endothelin in endothelial
dysfunction (Amiri et al., 2004) hypertension (Leung et al., 2011), renal
damage (Hocher et al., 1997; Shindo et al., 2002) and retinal degen-
eration (Mi et al., 2012). In addition, a role for astrocytic EDN1 in
neuropathic pain was demonstrated by transgenic mice in which the
glial ﬁbrillary acidic protein (GFAP) promoter drove expression of Edn1
(Lo et al., 2005). However, as with the developmental activity of
endothelin signaling, none of these approaches have provided the
ability to target Edn1 expression in a spatiotemporal manner, thus lim-
iting the utility of these mice in examining how EDN1 functions in
human disease.
Here we report the development of an inducible transgenic mouse
model in which the expression of Edn1 is regulated by Cre recombi-
nase. We show using the Wnt1-Cre transgenic mouse strain that
embryos from four independent lines of transgenic mice have varying
elevated levels of EDN1 protein, accompanied by jaw and midfacial
defects. These defects are preceded by changes in the expression of
genes involved in pharyngeal arch patterning. Because EDN1 can be
induced in any tissue at any age by selecting appropriate Cre strains,
these mice should prove useful to a variety of scientiﬁc ﬁelds.
Materials and methods
Transgene construction and animal production
To create an inducible Edn1 transgene, we ﬁrst used an expression
vector (pBALNLXGFP) in which CMV enhancer-chicken β-actin promo-
ter sequences are separated from a multiple cloning cassette by a loxP-
neomycin resistance-triple polyA-loxP “stop” cassette (a kind gift of Drs.
A Simeone and F. Tuorto, Institute of Genetics and Biophysics, Naples).
Due to the presence of restriction enzyme sites within the components
of our ﬁnal transgene, we had to rebuild the expression cassette in a
manner that would allow us to excise the ﬁnal transgene. All cloning
was conﬁrmed by restriction digest. We ﬁrst digested pBALNLXGFP
with SalI and ClaI to isolate the CMV enhancer-chicken β-actin promoter
sequences.We also digested pBALNLXGFPwith ClaI and EcoR1 to isolate
the loxP-neor/3xpolyA-loxP cassette (there is an internal SalI site within
the latter sequence which prevents isolation of the two sequences
together). The isolated sequences were gel puriﬁed (Gel Puriﬁcation Kit,
Qiagen). pBluescriptII SKþ was then digested with SalI and ClaI
followed by insertion of CMV enhancer-chicken β-actin promoter
sequences, creating the plasmid pBA). This plasmid was then cut with
ClaI and EcoR1 and the loxP-neor/3xpolyA-loxP cassette inserted. After
puriﬁcation, the resulting plasmid (pBN) was cut with NotI and blunted.
To generate a polyAþ sequence for the transgene, the SV40 polyAþ
sequence from pCS2þMT (pCS2þ containing a myc-tag sequence) was
ﬁrst cut with NotI, puriﬁed and then the ends blunted using Klenow
enzyme. After puriﬁcation, the plasmid was cut with XhoI and the SV40
polyAþ sequence isolated and gel puriﬁed. The sequence was then
cloned into pSP73 (Promega) cut with XhoI and SmaI. After puriﬁcation,
this plasmid (pSP-PA) was cut with XhoI and SacI, blunted and cloned
into the blunted pBN generated above. The resulting plasmid (pBNS)
was then digested with SmaI. The plasmid, pmET-1, containing a full
length clone of mouse Edn1, was cut with PstI and SmaI, puriﬁed,
blunted with T7 polymerase and the liberated band then gel puriﬁed
and cloned into the SmaI-digested pBNS. The resulting plasmid, pBN-
Edn1, containing the chicken b-actin-Edn1 (CBA-Edn1) transgene, was
veriﬁed by both restriction digests and sequencing. The plasmidwas cut
with KpnI to liberate the transgene from plasmid sequence, with the
transgene isolated and puriﬁed as previously described (Clouthier et al.,
1997). Injection of the transgenewas performed as previously described
(Clouthier et al., 1997). 22 founder CBA-Edn1 transgenic mice were
generated, with 10 used to establish stable lines. Of these, four were
chosen for subsequent analysis. The ofﬁcial nomenclature for theses
four lines is: B6.129-Tg(ACTB-Edn1)721Clou (MGI:5538246), B6.129-Tg
(ACTB-Edn1)1398Clou (MGI:5538247), B6.129-Tg(ACTB-Edn1)1408Clou
(MGI:5538248), and B6.129-Tg(ACTB-Edn1)1416Clou (MGI:5538249).
Embryo genotyping
CBA-Edn1 mice and embryos were genotyped by PCR analysis
using genomic DNA prepared from tail biopsies or amniotic sacs.
Genotyping was performed using the primers 50–CAG CGC GGT
CCT CAG CAA GT 30 and 50- ACC TCC CAC ACC TCC CCC TG 30.
Reactions were visualized on a 3% agarose gel. Successful ampli-
ﬁcation by PCR resulted in a 500 bp band. TheWnt1-Cre (Danielian
et al., 1998), Myf5-Cre (Tallquist et al., 2000) and R26R (Soriano,
1999) strains have been previously described. Cre and lacZ
genotyping were performed as previously described (Ruest and
Clouthier, 2009; Soriano, 1999). The ofﬁcial nomenclature for
the Wnt1-Cre, Myf5-Cre and R26R strains is: 129S4.Cg-Tg(Wnt1-
cre)2Sor/J, B6.129S4-Myf5tm3(cre)Sor/J) and B6.129S4-Gt(ROSA)
26Sortm1Sor/J.
Determination of transgene homozygosity
To determine homozygosity of CBA-Edn1 mice, a quantitative
real time PCR assay was performed in which a region correspond-
ing to part of the ﬁfth exon of Edn1 was ampliﬁed using the
following PCR primers: 50–GACCATCTGTGTGGCTTCTAC-30; 50–
GGAACACCTCAGCCTTTCTT-30. Primer function was veriﬁed in a
standard PCR reaction, in which they correctly ampliﬁed a 92 bp
fragment. Primers used to detect the Ramp3 gene (the internal
reference gene) have been previously described (Sakurai et al.,
2008). Brieﬂy, genomic DNA was extracted as described above for
genotyping. Ampliﬁcation was performed using the QuantiTect
SYBR Green PCR kit (Qiagen). Each PCR reaction contained 80 ng of
genomic DNA and 6.25 pmol of each primer. Reactions were
carried out on the MyiQ2 machine (BioRad) using the following
conditions: 95 1C for 2 min, followed by 40 cycles of 95 1C for 15 s,
60 1C for 30 s, and 72 1C for 1 min. Results were analyzed by the
ΔΔCt method, in which the 2ΔΔCt (fold change) was calculated
by subtracting the ΔCt (Ct for Edn1- Ct for Ramp3) of mutant
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embryos (homozygous and heterozygous) from the ΔCt of wild
type embryos.
Skeleton staining
Skeletal staining of E18.5 embryos with alizarin red (bone) and
alcian blue (cartilage) was performed as previously described
(Ruest et al., 2004). Stained embryos were analyzed and photo-
graphed using the Olympus SZX12 stereomicroscope ﬁtted with an
Olympus DP-11 digital camera. Seven embryos of each genotype
were stained and analyzed, with representative embryos from
each strain shown in the ﬁgures.
Quantitative real-time RT-PCR
One E10.5 CBA-Edn1;Wnt1-Cre embryo from the 1398 and 1416
lines and one E10.5 control embryo were harvested and stored in
RNAlater (Qiagen). Total RNA was extracted from whole embryos
using the RNeasy Micro Kit (Qiagen). cDNA was prepared from
total RNA using the QuantiTect cDNA Synthesis Kit (Qiagen). Real-
time quantitative PCR was performed using 5 ng of cDNA and the
QuantiTect SYBR Green PCR Kit (Qiagen) and QuantiTect Primer
Assays for Edn1 and Actb (β-actin; Qiagen). RT-PCR and data
analysis were performed using a MyiQ2 machine (BioRad). Data
analysis was performed using the ΔΔCt method as described
previously (Barron et al., 2011).
Whole mount in situ hybridization (ISH)
Whole mount ISH was performed as previously described (Clouthier
et al., 1998) with digoxigenin (DIG)-labeled antisense cRNA riboprobes
against Edn1 (Clouthier et al., 1998), Dlx3 (Clouthier et al., 2000) and
Dlx5 (Ruest et al., 2004) on three embryos from each line being exa-
mined. Onemodiﬁcationwas introduced for detection of Edn1message,
with the color development of embryos in (NBT) and (BCIP) performed
for two hours on ﬁve consecutive days. Overnight washes in TBST in the
dark at 4 1C were performed between each day of development. This
approach was used to increase the signal to noise ratio, a common
problem in analyzing Edn1 expression. Embryos were photographed
using an Olympus SZX12 microscope as described above.
Enzyme-linked immunoassay for EDN1 protein levels
Three E12.5 CBA-Edn1;Wnt1-Cre embryos from each of the four
lines and three E12.5 control embryos were harvested, snap frozen in
liquid nitrogen and stored at 80 1C. Whole embryos were homo-
genized using a Polytron PT 10–35 (Brinkmann) in 10 ml of 1 M acetic
acid containing 0.01 mM pepstatin A for 30 s. Homogenates were
immediately placed in a boiling water bath for 10min and then
centrifuged at 15,000g for 30 min. Supernatants were collected and
stored at 80 1C. To concentrate EDN1 protein, Sep-Pak Light C18
cartridges (Waters Corp., Milford, Massachusetts) were primed with a
sequence of solutions: 4% acetic acid/86% ethanol; absolute methanol;
distilled water; 4% acetic acid. Supernatants were thawed on ice and
applied to primed cartridges. Protein was eluted with 4% acetic acid/
86% ethanol and then lypholized using a centrifugal evaporator (Speed
Vac concentrator, Savant). The lyophilized product was resuspended in
sample diluent provided by the human Endothelin-1 immunoassay kit
(R&D Systems). This kit employs the quantitative enzyme immunoas-
say (EIA) technique by using an antibody speciﬁc for EDN1. Protein
concentration was measured by a Bradford assay (Biorad). Equal
amounts of protein per sample were then applied to individual wells
of the provided EIA 96-well plate alongside standard and control
samples provided in the EIA kit. Each plate was then placed in a
SpectraMax 190 microplate reader (Molecular Devices) and the optical
density of each well determined by taking readings at 450 nm before
correcting by subtracting the reading at 620 nm. The data is presented
as fold change between mutant and control embryos for each line,
with error bars representing standard deviation. Error analysis was
performed using an ANOVA model.
Analysis of cellular proliferation and apoptosis
Three E10.5 CBA-Edn1;Wnt1-Cre embryos each from lines 1398 and
1416 (and three control embryos) were collected, ﬁxed in 4% paraf-
ormaldehyde for 2 h on ice and then rinsed through graded ethanols
into xylene before parafﬁn embedding and sectioning along a trans-
verse plane at 7 μm. Detection of proliferating cells was performed
using 5-ethynyl-20-deoxyuridine (EdU) incorporation analysis and the
Click-iT EdU Imaging Kit (Life Technologies) with Alexa Fluor 594 as
the ﬂuorescent label. Detection of apoptosis was performed using the
In Situ Cell Death Detection kit (Roche), with ﬂuorescein as the
ﬂuorescent label. Both techniques were performed on the same slide
(Barron et al., 2011; Ishii et al., 2005). After both techniques were
performed, nuclei were labeled using DAPI. TUNEL, EdU and DAPI
ﬂuorescent staining was analyzed on an Olympus BX51 compound
microscope ﬁtted with a DP71 digital camera. TUNEL-positive cells
(green) were manually counted using ImageJ (NIH) and the cell
counter plugin. EdU (red) or DAPI (blue)-labeled cells were automa-
tically counted using ImageJ (NIH) and the analyze particle tool after
image threshold adjustment and binary processing. The apoptotic
index was calculated by dividing the number of TUNEL-positive cells
by the total number of cells (DAPI-positive). The proliferation index
was calculated by dividing the number of EdU-positive cells by the
total number of cells. Two planes of both maxillary prominences of
each embryo were used for cell counting. Statistical analysis was
performed using an unpaired two-tailed t-test.
Results and discussion
Creation and analysis CBA-Edn1 transgenic mice
To create a mouse strain in which Edn1 expression could be
induced in a speciﬁc spatio-temporal pattern in both embryos and
adults, we designed a transgene in which the chicken β-actin
promoter/enhancer sequence (CBA) was placed upstream of a
mouse Edn1 cDNA (Fig. 1A). In between these sequences, we
inserted a neomycin resistance cassette containing a 3X stop
sequence and ﬂanked by loxP sites. Of the 22 founder transgenic
mice generated with this construct, 10 were expanded into stable
transgenic lines and four were subsequently analyzed in detail
(data not shown). All four of these CBA-Edn1 lines produced the
expected number of hemizygous pups when crossed with wild
type animals (data not shown). Further, homozygous animals from
all four lines were achieved at the expected frequency from
hemizygous parents and were viable and healthy (data not
shown).
To begin characterization of each line, we examined embryos
following tissue-speciﬁc activation of the CBA-Edn1 transgene in NCCs.
This was accomplished by crossing CBA-Edn1 animals from all four of
our lines with mice from the Wnt1-Cre strain (Danielian et al., 1998).
Cre expression in this strain occurs in a Wnt1-expressing cell popula-
tion within the central nervous system (CNS) from which NCCs arise
(Echelard et al., 1994), making it an ideal strain in which to delete
genes involved in cranial NCC patterning and development (Chai et al.,
2000; Ruest and Clouthier, 2009). CBA-Edn1;Wnt1-Cre embryos were
ﬁrst collected at embryonic day (E) 12.5 and the amount of the mature
21 amino acid form of EDN1 measured using an enzyme-linked
immunoassay (EIA). Whole embryo extract was used, as this has been
previously shown to be a reliable indicator of EDN1 protein levels
(Clouthier et al., 1998) and allowed us to not pool embryos. We found
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that embryos from Line 1398 had a 2.64-fold increase in mature EDN1
levels, while embryos from Lines 1416 and 1408 had a 2.38-fold
increase and 1.95-fold increase, respectively, in mature EDN1 when
compared to control embryos (Fig. 1B). Embryos from Line 721 had a
1.84-fold increase in EDN1 levels. Similar results were obtained in a
qRT-PCR assay for Edn1 mRNA in whole E10.5 embryos from Lines
1398 and 1416 (Suppl. Fig. 1). These results conﬁrm that levels of
mature EDN1 were signiﬁcantly elevated in all four lines, though
differences between lines were not statistically signiﬁcant.
As described above, Cre expression in theWnt1-Cre strain results in
gene deletion in cells that give rise to NCCs (Danielian et al., 1998).
When crossed into the Cre reporter strain R26R, indelible β-
galactosidase (β-gal) activity is observed in NCCs and their derivatives
(Fig. 2D, H, L and (Abe et al., 2007; Chai et al., 2000)). To conﬁrm that
the CBA-Edn1 transgene was driving spatial Edn1 expression in a Cre-
dependent manner, we performed whole-mount in situ hybridization
(ISH) analysis for Edn1 using E8.5, E9.5 and E10.5 CBA-Edn1;Wnt1-Cre
embryos. Based on the EIA results, we focused our analysis on lines
1398 and 1416. In E8.5 control embryos, Edn1 expression was faintly
observed in the ﬁrst pharyngeal arch (Fig. 2A). In E8.5 CBA-Edn1;Wnt1-
Cre embryos from the 1398 line, broad Edn1 expression was observed
in the head, in streams extending from the hindbrain rhombomere 1/2
and 4 regions and in the ﬁrst pharyngeal arch (Fig. 2B). In embryos
from line 1416, expression was primarily limited to the ﬁrst phar-
yngeal arch mesenchyme (Fig. 2C). These patterns matched that of β-
galactosidase staining in E8.5 R26R;Wnt1-Cre embryos (Fig. 2D), in
which Cre expression results in indelible staining in expressing cells
and their daughter cells (Soriano, 1999). In E9.5 control embryos, Edn1
expression was present in the ectoderm lining the pharyngeal arches
(Fig. 2E). In E9.5 CBA-Edn1;Wnt1-Cre embryos from the 1398 (Fig. 2F)
and 1416 (Fig. 2G) lines, Edn1 message was additionally observed in
the pharyngeal arches and frontonasal prominence, again matching β-
galactosidase staining in E9.5 R26R;Wnt1-Cre embryos (Fig. 2H). In
E10.5 control embryos, Edn1 expression was not detected in the
pharyngeal arches or frontonasal prominence of the embryo, though
expressionwas observed in the optic and otic placodes (Fig. 2I). In con-
trast, ectopic Edn1 expression in E10.5 CBA-Edn1;Wnt1-Cre embryos
was observed in the mandibular and maxillary portions of the ﬁrst
pharyngeal arch and frontonasal prominence from lines 1398 (Fig. 2J)
and 1416 (Fig. 2K). Weak expression could also be detected proximally
to the pharyngeal arches in embryos from both lines (Fig. 2J, and K).
This pattern matched that of β-galactosidase staining in E10.5 R26R;
Wnt1-Cre embryos (Fig. 2F), including the more proximal staining,
likely representing the developing cranial nerves. Similar staining was
observed in E10.5 CBA-Edn1;Wnt1-Cre embryos from line 721 (Suppl.
Fig. 2C). We were unable to detect ectopic Edn1 expression in E10.5
CBA-Edn1;Wnt1-Cre embryos from the 1408 line (Suppl. Fig. 2B).
To continue our analysis, E18.5 CBA-Edn1;Wnt1-Cre embryos were
stained with alizarin red and alcian blue to allow visualization of bone
and cartilage, respectively. Analysis of stained embryos revealed that
distinct craniofacial malformations were present in three of the four
lines (Fig. 3 and Suppl. Fig. 3). Based on the EIA and ISH results, we
continued our focus on lines 1398 and 1416. E18.5 CBA-Edn1;Wnt1-Cre
embryos from Line 1398 presented with a complete homeotic tran-
sformation of the upper jaw (maxilla and jugal bones) into a
mandible-like structure, complete with duplicated angular and con-
dylar processes (Fig. 3B, K, and N). The coronoid process of the
mandible appeared to be lost due to fusion of the mandible and
duplicated mandible (Fig. 3B, K, and N). The malleus and incus were
present, though additional cartilage was present that appeared to
represent duplication of the malleus and incus (Fig. 4B). The tympanic
ring and gonial bone were present but hypoplastic. An ectopic bone
was present suggestive of duplicated gonial bone and/or part of the
tympanic ring (Fig. 4B). The duplicated incus appeared similar to the
structure identiﬁed as a duplicated malleus reported for embryos in
which Edn1 was knocked into the Ednra locus (Sato et al., 2008a). In
addition, the squamosal (Fig. 3B) and palatine (Fig. 3E) bones were
hypoplastic, the latter resulting in a palatal cleft. E18.5 CBA-Edn1;
Wnt1-Cre embryos from Line 1416 showed more signiﬁcant defects
that included a transformation of the maxilla into a mandible-like
structure, complete with a duplicated Meckel's cartilage and hypopla-
sia of the squamosal (Fig. 3C) and palatine (Fig. 3F) bones. As with
embryos from line 1398, the condylar and angular processes were also
duplicated, while the coronoid process was lost (Fig. 3C, L, and O).
Middle ear elements including the tympanic ring and malleus were
present but hypoplastic (Fig. 4C). However, the remainder of the
middle ear was composed of a large piece of ectopic cartilage, making
identiﬁcation of the incus or aberrant cartilage structures impossible
(Fig. 4C). In addition, in 70% of CBA-Edn1;Wnt1-Cre embryos from the
1416 line, a large mid-facial cleft was also present (Fig. 3F, and I). The
cleft did not affect the transformation of the maxilla, suggesting that
these two events are not related to each other. CBA-Edn1;Wnt1-Cre
embryos from line 721 resembled those from line 1416 (Suppl. Fig. 3C,
F, and I). In contrast, craniofacial malformations were not present in
CBA-Edn1;Wnt1-Cre embryos from line 1408 (Suppl. Fig. 3B, E, and H).
Overall, the presence of ectopic Edn1 appears to correlate with the
presence of defects in the developing jaw region. However, based on
the comparison of ISH/phenotype results with the EIA results, there
are likely differences between EDN1 levels that are not detectable by
ISH, potentially reﬂecting chromatin dynamics of the insertion site (Li
et al., 2002; Pikaart et al., 1998; Prioleau et al., 1999; Ryan et al., 1989)
Although homeotic transformation of the maxilla into a mandible-
like structure was apparent in mice in which an Edn1 cDNA was inse-
rted into the Ednra locus (EdnraEdn1/þ), a midfacial cleft was not
observed (Sato et al., 2008a). Without EIA measurement of mature
EDN1 levels in EdnraEdn1/þ embryos, it is impossible to compare the
Fig. 1. Creation of conditional CBA-Edn1 transgenic mice. A. Design of the CBA-Edn1
conditional transgene. The chicken β-actin (ACTB) promoter is separated from a
mouse Edn1 cDNA by a neomycin resistance cassette (neor) ﬂanked by loxP sites.
The neor cassette contains a 3X stop sequence, preventing read-through into the
Edn1 cDNA. Crossing CBA-Edn1 transgenic mice with mice expressing Cre results in
excision of the neor cassette and thus expression of Edn1. B. EDN1 protein levels in
E12.5 CBA-Edn1;Wnt1-Cre embryos. CBA-Edn1 animals from all four lines were bred
with mice from the Wnt1-Cre strain. Resulting CBA-Edn1;Wnt1-Cre embryos were
collected at E12.5 and the level of mature EDN1 for each line measured using an
enzyme-linked assay (EIA) (n¼3 embryos for each line). The amount of EDN1 is
presented as fold-increase over EDN1 levels in control embryos. Error bars
represent standard error.
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EDN1 levels between EdnraEdn1/þ and CBA-Edn1;Cre embryos. How-
ever, it is conceivable that Edn1 expression is higher in CBA-Edn1;Cre
transgenic embryos than that coming from the additional one copy
found in EdnraEdn1/þembryos and that this subsequently leads to the
midfacial cleft in CBA-Edn1;Cre embryos. We also cannot rule out the
possibility that the phenotypic outcome of increased EDN1 in Edn-
raEdn1/þembryos is partially masked due to reduced EDNRA signaling
that occurs when Ednra gene dosage is reduced (Vieux-Rochas et al.,
2010).
EDNRA signaling in the mandibular pharyngeal arches initiates
a cascade of gene expression required for establishing the identity
of NCCs in the mandibular arch (Ruest et al., 2004) (Clouthier et al.,
2010). We thus expected that EDNRA-dependent gene expression
normally conﬁned to the mandibular portion of the ﬁrst phar-
yngeal arch would expand into the maxillary prominence, some-
thing observed previously in EdnraEdn1/þ embryos (Sato et al.,
2008a). Indeed, expression of Dlx3 expanded in CBA-Edn1 embryos
from both the 1398 (Fig. 5B) and 1416 (Fig. 5C) lines, with this
expanded expression observed in the rostral mandibular arch
mesenchyme, overlying rostral ectoderm and maxillary promi-
nence ectoderm. In CBA-Edn1 embryos from the 1416 line, this
maxillary expression extended into the lambdoidal junction
(arrow in Fig. 5C). Similarly, aberrant Dlx5 expression was
observed extending from the mandibular arch into the maxillary
prominence in both lines (Fig. 5E, and F). These ﬁndings suggest
that upregulation of EDRNA signaling in the maxillary prominence
leads to an EDNRA-dependent gene expression program that
subsequently leads to homeosis of maxillary structures.
It is surprising that we did not see more substantial changes in
mandible development, though major defects were also not observed
in embryos in which Edn1 was knocked into the Ednra locus (Sato
et al., 2008a). We have previously shown that there is a threshold level
of EDN1 required for normal lower jaw development during a narrow
window of arch development (Clouthier et al., 2003), with EDN1
activity dispensable after E9.5 (Clouthier et al., 2003; Ruest et al.,
2005). Taken with the current ﬁndings, it is likely that EDN1 activity
patterns all cells within a region (meaning that there is not a gradient
of action), a hypothesis supported by in vivo rescue experiments in
edn1 mutant zebraﬁsh embryos (Miller et al., 2000b). In addition, even
though the levels remain high later in arch development, the ability to
respond to EDN1 likely diminishes.
Elevated EDN1 levels do not lead to changes in NCC proliferation or
survival
Increased Edn1 expression in cranial NCCs could lead to midfacial
clefts for several reasons, including disrupted NCC migration, pro-
liferation or survival. A defect in migration seems less likely, as EDN1
typically acts as an attractant for multiple cell types, including
astrocytes (Kuhlmann et al., 2005) and both trophoblast (Liu et al.,
2012) and chondrosarcoma (Wu et al., 2013) cells. In addition, loss of
EDNRA signaling does not lead to detectable changes in NCC
migration into the mandibular portion of the ﬁrst arch (Abe et al.,
2007), further suggesting that EDN1 functions at time periods after
NCC migration is complete. In contrast, EDN1 has been associated
with proliferation of multiple cell types, including endothelial
Fig. 2. Detection of Edn1 expression in CBA-Edn1;Wnt1-Cre embryos. Whole-mount in situ hybridization for Edn1 in E8.5 (A–C), E9.5 (E–G) and E10.5 (I–K) control (A, E, I)
and mutant embryos from the 1398 (B, F, J) and 1416 (C, G, K) lines. Embryos are shown in lateral view. A–D. At E8.5, endogenous Edn1 expression was conﬁned to ﬁrst
pharyngeal arch (1) (A). In contrast, ectopic Edn1 expression in embryos from the 1398 line was observed in the ﬁrst pharyngeal arch (1), head and in streams from the
hindbrain (arrows) (B). In embryos from line 1416, ectopic Edn1 expressionwas primarily only observed in the ﬁrst arch (C). This pattern was consistent with that observed in
E8.5 R26R;Wnt1-Cre embryo stained in whole-mount for β-gal activity (D). E–H. At E9.5, endogenous Edn1 expression was conﬁned to the ectoderm and endoderm
surrounding the mandibular portion of arch 1 and arches 2, 3 and 4 (E). The mesodermal core shows endogenous expression of Edn1 at this age (E). In E9.5 embryos from the
1398 (F) and 1416 (G) lines, ectopic Edn1 expression was observed in pharyngeal arches 1–4 and in the fronto-nasal prominence (fnp). A similar pattern was observed in E9.5
R26R;Wnt1-Cre embryos (H). I–L. At E10.5, endogenous Edn1 expression was conﬁned to the optic (opt) and otic placodes and the pharyngeal arch endoderm between arches
1 and 2 (I). In E10.5 embryos from the 1398 (J) and 1416 (K) lines, ectopic Edn1 expression was observed in pharyngeal arches 1–4 and in the (fnp). Weaker ectopic staining
was observed proximal to arches in an area in which the cranial nerves form. This pattern was similar to that observed in E10.5 R26R;Wnt1-Cre embryos (L). ct, conotruncus;
h, heart; mx1, maxillary prominence of ﬁrst pharyngeal arch; md1, mandibular portion of ﬁrst pharyngeal arch.
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(Kuhlmann et al., 2005) and colon cancer cells (Grant et al., 2007),
while also often associated with inhibition of apoptosis in multiple
cellular settings (Del Bufalo et al., 2002; McWhinnie et al., 2007;
Nelson et al., 2005; Shichiri et al., 2000). To determine whether the
observed midfacial clefts could be due to early changes in NCC
proliferation and/or survival within the developing maxillary promi-
nences, we performed both cell proliferation and apoptosis analysis.
These analyses were performed on the same sections through two
planes of the maxillary prominence in E10.5 embryos. At this age, we
did not observe signiﬁcant differences in either proliferation or
apoptosis of cells in the maxillary prominence (Fig. 6A–D) between
control and CBA-Edn1;Wnt1-Cre embryos from the 1398 and 1416
lines. The apoptosis index in embryos from Line 1416 trended higher
(p¼0.08), with the variation in cell death between embryos also
higher in this line than in Line 1398 (data not shown). Higher cell
death in some Edn1;Wnt1-Cre embryos from the 1416 line may point
to embryos that will go on to show a midfacial cleft at E18.5, though
it is currently not possible to prove such a correlation. Overall, our
results suggest that Edn1 overexpression does not lead to an
immediate change in NCC-derived mesenchyme growth or survival
during their initial patterning period. Rather, the observed defects
likely arise during later differentiation of the NCC derived mesench-
yme. Similar midfacial defects have recently been described in
embryos containing phosphorylation variants of the bHLH factor
Hand1 (Firulli et al., 2014). While the basis for the defects in these
embryos is not completely clear, Hand1 is a downstream mediator of
EDNRA signaling, suggesting the cellular affect of the two may share
a common mechanism. Further detailed analysis of gene expression
associated with midline development during early facial patterning
will be required to address these questions.
Fig. 3. Skull analysis of E18.5 CBA-Edn1;Wnt1-Cre embryos. A–O. Alizarin red and alcian blue stained skulls to visualize bone and cartilage, respectively. A–C: Lateral view of
skulls. D–F: Ventral view of the skull. G–I: Dorsal view of the skull. J–L. Lateral view of lower and upper jaw structures. M–O. Ventral view of lower and upper jaw structures.
Distinct craniofacial malformations were observed in embryos from lines 1398 (B, E, H, K, N) and 1416 (C, F, I, L, O) when compared to control embryos (A, D, G, J, M). Both
lines presented with transformation of the maxilla (mx) into a mandible-like structure (md*) that was fused with the mandible (md). The duplicated mandible contained a
duplicated Meckel's cartilage (mc*), absent jugal bones (j) and deformed squamosal (sq) bones, absent or hypoplastic palatine (pl) and basisphenoid (bs) bones, and a palatal
cleft (arrow). 70% of embryos from line 1416 (F, I) also presented with a large mid-facial cleft. ap, angular process; ap*, duplicated angular process; bo, basisoccipital; cdp,
condylar process; cdp*, duplicated condylar process; crp, coronoid process; f, frontal bone; h, hyoid; j, jugal; n, nasal bone; p, parietal bone; pmx, pre-maxilla; pt, pterygoid;
sq, squamosal bone; ty, tympanic ring; zps, zygomatic process of the squamosal bone.
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Defects in CBA-Edn1;Myf5-Cre embryos
To illustrate that Edn1 expression could be induced by other Cre
strains, we took advantage of the mesoderm-speciﬁc Cre strain
Myf5-Cre (Tallquist et al., 2000). This strain was crossed into our
four CBA-Edn1 strains and embryos collected at E10.5 for whole
mount ISH. In three of our four lines, ectopic Edn1 expression was
observed in somitic mesoderm and brain (Fig. 7C–E) in a similar
pattern to that observed for β-gal staining in E10.5 R26R;Myf5-Cre
embryos (Fig. 7F). We were unable to detect ectopic Edn1 expres-
sion in embryos from Line 1408 (Fig. 7B). These data suggest that
Edn1 expression in at least three of our CBA-Edn1 transgenic
mouse strains can be achieved at likely any age through the use
of tissue and/or temporally regulated Cre transgenic mouse
strains.
To determine whether aberrant Edn1 expression induced skeletal
changes in CBA-Edn1;Myf5-Cre embryos, bone and cartilage-stained
E18.5 embryos from all four lines were examined. Because of the
ectopic Edn1 expression in somites, we ﬁrst examined the thoracic
skeleton. In all four lines, fusions between the ﬁrst and second costal
cartilages were observed (Fig. 7H–K), with varying other costal
cartilage fusions observed in embryos from lines 1398, 1408 and
1416 (Fig. 7I–K). In lines 1398, 1408 and 1416, fusions were also
observed between adjoining ribs (Fig. 7I–K). There did not appear to
be a speciﬁc pattern to the fusions, as they were not bilaterally sym-
metric in a single embryo (data not shown). However, while the
pattern of defects differed between sides, the overall severity of rib
defects was similar between embryos of a speciﬁc line (data not
shown). These changes may reﬂect defects in dermamyotome dev-
elopment due to EDN1 action. Myf5 is expressed in the dorsomedial
Fig. 4. Middle ear defects in CBA-Edn1;Wnt1-Cre embryos. Dissected middle ear structures after staining with alizarin red and alcian blue to visualize bone and cartilage,
respectively. A. The middle ear from a control embryo, showing the three middle ear ossicles: malleus (m), incus (i) and stapes (s) in addition Meckel's cartilage (mc) and the
gonial bone (g). B. In CBA-Edn1;Wnt1-Cre embryos from line 1398, middle ear defects included an imperfect duplication of the malleus (m*) and incus (i*). There was also
additional bone present that could be a duplicated but malformed tympanic ring (ty*) or gonial (g*) bone, though the poor shape prevented a deﬁnitive identiﬁcation. C. In
CBA-Edn1;Wnt1-Cre embryos from line 1416, the malleus and tympanic ring were present but hypoplastic. The remainder of the middle ear was composed of an
unidentiﬁable ectopic cartilage.
Fig. 5. Disrupted gene expression in E10.5 CBA-Edn1;Wnt1-Cre embryos. A–F. Lateral view of embryos from lines 1398 (B, E) and 1416 (C, F) processed for whole mount in situ
hybridization (ISH) analysis using digoxigenin-labeled probes. In embryos from both lines, there was ectopic expression of Dlx3 in the rostral arch mesenchyme and
overlying ectoderm of the mandibular arch and in the maxillary prominence around the lamdoidal junction (arrows in B and C). Likewise, a proximal expansion of Dlx5
towards the maxillary prominence was observed (arrow in E and F). 1. ﬁrst pharyngeal arch; 2. second pharyngeal arch.
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aspects of the dermamyotome (Cossu et al., 1996), with the devel-
opment of both ribs and dermamytome-derived intercostal muscles
disrupted inMyf5Jae/Jae mutants (Kablar et al., 1997). Pdfga expression
in Myf5Jae/Jae mutant embryos is downregulated in the myotome,
suggesting that PDGFA is a direct or indirect target of MYF5 during
myotome development (Tallquist et al., 2000). While expression of
Pdgfa from theMyf5 locus (Myf5PDGFA/PDGFA ) rescues the rib formation
defects observed in Myf5ae/Jae mutant embryos, extensive fusions
between ribs exist (Tallquist et al., 2000). These fusions have been
hypothesized to result from the intercostal muscle defects (Tallquist
et al., 2000), since the intercostal muscles normally separate forming
ribs (Huang et al., 2000). It is thus plausible that expression of Edn1
in the dermamyotome disrupts intercostal development, potentially
through induction of early cell death. Similar rib fusions are observed
in Splotchmutants, in which loss of Pax3 results in failure to maintain
Pdgfra expression and subsequent elevated apoptosis in the somites
by E12.5 (Conway et al., 1997). Similar apoptosis patterns have been
found in Pdgfra mutant embryos (Soriano, 1997). Whether EDN1
affects these pathways or inﬂuences cellular patterning and survival
will require further analysis.
While rib changes were evident in all lines, one CBA-Edn1;Myf5-
Cre embryo from the 1416 line had a partial homeotic transformation
of the maxilla into a mandible (Suppl. Fig. 4). Because this change has
to result from changes in NCC patterning, this implies a non-cell
autonomous action of EDN1 derived from mesodermal cells in the
pharyngeal arches. While ectopic Edn1 expression in the pharyngeal
arch region does not appear robust, the source of EDN1 is almost
certainly from the facial region, as pre-pro-EDN1 has a half-life of
around 15 min (Inoue et al., 1989) and typically acts close to its site of
activation from an inactive to active form by endothelin converting
enzyme-1 (ECE1) (Yanagisawa et al., 1998b). This mode of non-cell
autonomous action of EDN1 matches that of its normal mode of
action during mandibular arch patterning, when EDN1 from primar-
ily the ectoderm drives EDNRA signaling (Nair et al., 2007; Tavares
et al., 2012). While it is possible that EDN1 caused changes affecting
migration, proliferation or survival of NCCs prior to their arrival in the
arches of CBA-Edn1;Myf5-Cre embryos, such changes were not
observed even when EDN1 activity occurred in NCCs prior to the
onset of migration (via Wnt1-Cre activity). This further indicates that
EDN1 action occurs in the arches.
We cannot completely exclude the possibility that Cre expression
is leaky in the Myf5-Cre line, resulting in Cre activity in NCCs (and
thus a cell autonomous explanation), though Cre expression inMyf5-
Cre mice was achieved by inserting Cre into the Myf5 locus (Tallquist
et al., 2000). In addition, none of the 48 studies associated with this
strain have reported expression of Cre in NCCs (http://jaxmice.jax.
org/strain/007893.html). Finally, we have previously shown using
R26R;Myf5-Cre embryos that β-gal-positive cells are not observed in
either NCCs or their daughter cells (Tavares et al., 2012). Together,
these studies support the idea that the skull changes observed in
CBA-Edn1;Myf5-Cre embryo occur in a non-cell autonomous manner.
In conclusion, we have created four lines of CBA-Edn1 transgenic
mice in which the expression of Edn1 is prevented by the inclusion of
a strong stop cassette between the CBA promoter/enhancer sequence
and EDN1. As the stop cassette is ﬂanked by loxP sites, Edn1 expression
can be induced in a spatio-temporal manner in both embryos and
Fig. 6. Cell proliferation and death in CBA-Edn1;Wnt1-Cre embryos. A–C. Representative sections showing the maxillary prominence region of E10.5 control embryos (A) and
E10.5 embryos from lines 1398 (B) and 1416 (C). Cell proliferation was detected and quantiﬁed on sections from EdU-treated embryos after EdU-incorporation staining (red).
Cell death (TUNEL) was detected and quantiﬁed on the same sections (green). Nuclei were counterstained with DAPI (blue). D. The total number of cells (DAPI) and labeled
cells (TUNEL or EdU) were counted and the apoptosis and proliferation indexes calculated as the total number of TUNEL- or EdU-positive cells divided by the total number of
DAPI-positive cells. There was no signiﬁcant differences (n.s.) in either proliferating cells (1398: p¼0.1; 1416: p¼0.5) or cells undergoing apoptosis (1398: p¼0.2; 1416:
p¼0.08) relative to control embryos. Error bars represent standard error.
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adult mice by crossing Edn1 transgenic mice with appropriate Cre
transgenic mouse strains. These mice should be useful in further und-
erstanding mechanisms of EDN1 action during NCC patterning and
early vasculature development. In addition, it is likely that these mice
can be used to both understand how EDN1 activation in numerous
adult diseases contributes to the disease phenotype and determine the
beneﬁt of pharmaceutical intervention of EDN1 action as a treatment
paradigm.
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